6620 Share Price Performance
NT$81.90
5.00 (6.50%)
Price NT$81.90
Share PriceNT$81.90
6620 Community Narratives
There are no narratives available yet.
Recent 6620 News & Updates
No updates
Handa Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 2.99
- Gross Margin
- 99.86%
- Net Profit Margin
- 56.91%
- Debt/Equity Ratio
- 0%
Handa Pharmaceuticals, Inc. Competitors
About 6620
- Founded
- 2014
- Employees
- n/a
- CEO
- WebsiteView website
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis and heartburn associated with symptomatic non-erosive gastroesophageal reflux disease; HND-004 for treating diabetes; HND-032 for smoking cessation; and HND-026, a GI drug. Handa Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Tainan City, Taiwan.
Taiwanese Market Performance
- 7 Days: 2.5%
- 3 Months: 14.5%
- 1 Year: 10.3%
- Year to Date: 4.5%
The market has climbed 2.1% in the last 7 days, lead by the Information Technology sector with a gain of 2.3%. In the last year, the market has climbed 13%. Earnings are forecast to grow by 13% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading